<html><head><title>Jain Foundation Inc | Research Database | Dysferlin interacting proteins | Calpain-3</title><meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1"><link rel="stylesheet" href="../style-old.css" type="text/css" /></head><body leftmargin="0" topmargin="10" marginwidth="0" marginheight="10"><? include 'includes/main.php'; ?>            <td valign="top" align="center"><table width="92%" border="0" cellspacing="0" cellpadding="0">              <tr>                <td valign="top" height="13"></td>              </tr>              <tr>                <td><p class="section style3">Research Database</p>				<p><a href="database_dysferlin interactors.php">&lt;&lt;Back</a></p>                      <p><strong>Calpain-3</strong></p>                      <strong>1. What is Calpain-3?</strong>					  <p>Calpains are intracellular Ca++ modulated non-lysosomal cys-proteases. Calpain-3 is primarily expressed in skeletal muscle.</p>					  <strong>2. How was the interaction between Calpain-3 and Dysferlin demonstrated?</strong>					  <p>Dysferlin and Calpain-3 were shown to interact by coimmunoprecipitation in human muscle homogenates. Full-length as well as degradation products of Calpain-3 were shown to interact. 					  <br><em>Huang et al., European Journal of Human Genetics 13 (6): 721-730</em></br></p>					  <strong>3. Have knock-out mice been generated for Calpain-3? If yes, what is their phenotype?</strong>					  <p>Yes, Calpain-3 knockout mice have been generated. They have small foci of muscle necrosis, and though myogenic cells fuse normally, they lack well-organized sarcomeres.					  <br><em>Kramerova et al., Human Molecular Genetics 13 (13): 1373-1388</em></br></p>					  <strong>4. Are there any naturally occurring Calpain-3 mutations and/or deficiencies know to be associated with human disorders?</strong>					  <p>Primary mutations in Calpain-3 cause LGMD2A.</p>					  <p><strong>5.	How are the levels of Calpain-3 secondarily affected in case of Dysferlin-deficiency?</strong></p>					  Secondary reduction in Calpain-3 levels were reported in eight out of sixteen cases of LGMD2B.                      <em><br>Anderson, Neuromuscular Disorders 10 (8): 553-559</em></br><p>However, microarray studies in Dysferlin-deficiencies did not show any changes in Calpain-3 transcript levels.<br>Patients: <em>Campanaro et al., Human Molecular Genetics 11 (26): 3283-3298</em></br><br>Mice: <em>Hagena et al., Neuromuscular Disorders 15 (12): 863-877</em></br>                  </p></td>              </tr>              <tr>                <td>&nbsp;</td>              </tr>            </table></td>          </tr>          <tr>            <td bgcolor="#FDFFC6" align="center" valign="top">&nbsp;</td>            <td bgcolor="ffffff">&nbsp;</td>          </tr>          <tr>            <td height="30" align="right" bgcolor="#FDFFC6"></td>            <td height="30" align="right" valign="middle" bgcolor="#FDFFC6"><p class="footer">                <? include 'includes/footer.php'; ?>              </p>            </td>          </tr>        </table></td>        <td background="../images/bg_dot.gif" width="1"></td>      </tr>    </table>    <table width="780" border="0" cellspacing="0" cellpadding="0">      <tr>        <td height="4" background="../images/bg_green.gif"></td>      </tr>    </table>		</td>  </tr></table></body></html>